These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
68 related articles for article (PubMed ID: 7824508)
1. Immunohistochemical analysis of cathepsin D in prostate carcinoma. Makar R; Mason A; Kittelson JM; Bowden GT; Cress AE; Nagle RB Mod Pathol; 1994 Sep; 7(7):747-51. PubMed ID: 7824508 [TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of cathepsin D and epidermal growth factor receptor in prostate carcinoma. Maygarden SJ; Novotny DB; Moul JW; Bae VL; Ware JL Mod Pathol; 1994 Dec; 7(9):930-6. PubMed ID: 7892162 [TBL] [Abstract][Full Text] [Related]
4. High-grade foamy gland prostatic adenocarcinoma on biopsy or transurethral resection: a morphologic study of 55 cases. Zhao J; Epstein JI Am J Surg Pathol; 2009 Apr; 33(4):583-90. PubMed ID: 19033862 [TBL] [Abstract][Full Text] [Related]
6. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate. Sheridan T; Herawi M; Epstein JI; Illei PB Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190 [TBL] [Abstract][Full Text] [Related]
7. Metallothionein expression in prostatic carcinoma: correlation with Gleason grade, pathologic stage, DNA content and serum level of prostate-specific antigen. Moussa M; Kloth D; Peers G; Cherian MG; Frei JV; Chin JL Clin Invest Med; 1997 Dec; 20(6):371-80. PubMed ID: 9413634 [TBL] [Abstract][Full Text] [Related]
8. Cathepsin D and epidermal growth factor receptor immunohistochemistry does not predict recurrence of prostate cancer in patients undergoing radical prostatectomy. Moul JW; Maygarden SJ; Ware JL; Mohler JL; Maher PD; Schenkman NS; Ho CK J Urol; 1996 Mar; 155(3):982-5. PubMed ID: 8583622 [TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical staining and serotest markers during development of a sarcomatoid and small cell prostate tumor. Frković-Grazio S; Kraljić I; Trnski D; Tarle M Anticancer Res; 1994; 14(5B):2151-6. PubMed ID: 7840515 [TBL] [Abstract][Full Text] [Related]
10. Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma. Sinha AA; Quast BJ; Wilson MJ; Fernandes ET; Reddy PK; Ewing SL; Gleason DF Cancer; 2002 Jun; 94(12):3141-9. PubMed ID: 12115346 [TBL] [Abstract][Full Text] [Related]
11. Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases. Osunkoya AO; Hansel DE; Sun X; Netto GJ; Epstein JI Am J Surg Pathol; 2008 Mar; 32(3):461-7. PubMed ID: 18300803 [TBL] [Abstract][Full Text] [Related]
12. [Cathepsin D expression in primary breast cancer. Comparison of immunohistochemical and biochemical results]. Göhring UJ; Ingenhorst A; Crombach G; Scharl A Pathologe; 1993 Dec; 14(6):313-7. PubMed ID: 8121884 [TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate. Herawi M; Epstein JI Am J Surg Pathol; 2007 Jun; 31(6):889-94. PubMed ID: 17527076 [TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical staining of precursor forms of prostate-specific antigen (proPSA) in metastatic prostate cancer. Parwani AV; Marlow C; Demarzo AM; Mikolajczyk SD; Rittenhouse HG; Veltri RW; Chan TY Am J Surg Pathol; 2006 Oct; 30(10):1231-6. PubMed ID: 17001152 [TBL] [Abstract][Full Text] [Related]
15. Reduced 15-lipoxygenase-2 immunostaining in prostate adenocarcinoma: correlation with grade and expression in high-grade prostatic intraepithelial neoplasia. Jack GS; Brash AR; Olson SJ; Manning S; Coffey CS; Smith JA; Shappell SB Hum Pathol; 2000 Sep; 31(9):1146-54. PubMed ID: 11014584 [TBL] [Abstract][Full Text] [Related]
16. Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate. Uetsuki H; Tsunemori H; Taoka R; Haba R; Ishikawa M; Kakehi Y J Urol; 2005 Aug; 174(2):514-8. PubMed ID: 16006883 [TBL] [Abstract][Full Text] [Related]
17. Coordinate expression of cytokeratins 7 and 20 in prostate adenocarcinoma and bladder urothelial carcinoma. Bassily NH; Vallorosi CJ; Akdas G; Montie JE; Rubin MA Am J Clin Pathol; 2000 Mar; 113(3):383-8. PubMed ID: 10705819 [TBL] [Abstract][Full Text] [Related]